Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients
- 5 November 2013
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 54 (2) , 206-214
Abstract
Fosamprenavir (FPV) is the phosphate ester prodrug of the HIV-1 protease inhibitor amprenavir (APV). A pediatric population pharmacokinetic model for APV was developed and simulation was used to identify dosing regimens for pediatric patients receiving FPV in combination with ritonavir (RTV) which resulted in concentrations similar to those in adults receiving FPV/RTV 700/100 mg BID. Pharmacokinetic data was obtained from HIV infected subjects aged 2 months to 18 years receiving either FPV or FPV/RTV. A two-compartment model with first order absorption and elimination was an appropriate structural model. Significant covariates in the model included RTV coadministration on clearance, fed status on bioavailability for the oral suspension, body weight on clearance and volume terms, black race on clearance, and age on clearance. The following FPV/RTV twice daily dosing regimens in pediatric patients delivered plasma APV exposure similar to adults: 45/7 mg/kg in patients weighing <11 kg, 30/3 mg/kg in patients weighing 11 to <15 kg, 23/3 mg/kg in patients weighing 15 to <20 kg, and 18/3 mg/kg in patients weighting ≥20 kg. Additionally children weighing ≥39 kg can receive the adult regimen.Keywords
This publication has 14 references indexed in Scilit:
- PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV‐1 infectionHIV Medicine, 2009
- Differential Inhibition of Cytochrome P450 3A4, 3A5 and 3A7 by Five Human Immunodeficiency Virus (HIV) Protease Inhibitorsin vitroBasic & Clinical Pharmacology & Toxicology, 2006
- FosamprenavirClinical Pharmacokinetics, 2006
- Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor AmprenavirAntimicrobial Agents and Chemotherapy, 2004
- Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected PatientsAntimicrobial Agents and Chemotherapy, 2004
- Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and RitonavirAntimicrobial Agents and Chemotherapy, 2002
- In Vivo Effect of α 1 -Acid Glycoprotein on Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Protease InhibitorAntimicrobial Agents and Chemotherapy, 2001
- Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral DosingAntimicrobial Agents and Chemotherapy, 2001
- Metabolism of Amprenavir in Liver Microsomes: Role of CYP3A4 Inhibition for Drug InteractionsJournal of Pharmaceutical Sciences, 1998
- Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus TherapyThe Journal of Infectious Diseases, 1995